Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α

Journal of Virology

Volumn 87, Issue 1, 2013, Pages 137-147

  Hao, Junli ^a   Jin, Wensong ^a   Li, Xinghui ^a   Wang, Saifeng ^a   Zhang, Xiaojun ^a   Fan, Hongxia ^a   Li, Changfei ^a   Chen, Lizhao ^a   Gao, Bin ^a   Liu, Guangze ^b   Meng, Songdong ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b 458th Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLIN G1; MESSENGER RNA; MICRORNA 122; NT5C3 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

3' UNTRANSLATED REGION; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG BINDING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NORTHERN BLOTTING; NTC3 GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; VIRUS EXPRESSION; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION;

CELL LINE; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; MICRORNAS;

HEPATITIS B VIRUS;

EID: 84871967004     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01710-12     Document Type: Article

References (51)

1. Neuveut C, Wei Y, Buendia MA. 2010. Mechanisms of HBV-related hepatocarcinogenesis. J. Hepatol. 52:594-604.
2. Rudin D, Shah SM, Kiss A, Wetz RV, Sottile VM. 2007. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int. 27: 1185-1193.
3. Ter Borg MJ, Hansen BE, Bigot G, Haagmans BL, Janssen HL. 2008. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J. Clin. Virol. 42:160-164.
4. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. 2009. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 137:2002-2009.
5. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot- Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. 2009. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151-1157.
6. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. 2010. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 52:1251-1257.
7. Yang J, Zhao LS. 2009. Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report. Virol. J. 6:97.
8. Mao R, Zhang J, Jiang D, Cai D, Levy JM, Cuconati A, Block TM, Guo JT, Guo H. 2011. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocytederived cells. J. Virol. 85:1048-1057.
9. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-568.
10. Wu M, Xu Y, Lin S, Zhang X, Xiang L, Yuan Z. 2007. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J. Gen. Virol. 88:3260-3269.
11. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT. 2010. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J. Virol. 84:9332-9340.
12. Zhang Q, Wang Y, Wei L, Jiang D, Wang JH, Rao HY, Zhu L, Chen H, Fei R, Cong X. 2008. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro. J. Gastroenterol. Hepatol. 23: 1747-1761.
13. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, Casanova JL. 2008. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol. Rev. 226:29-40.
14. Lütgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, Lohse AW, Petersen J, Dandri M. 2011. Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology 140:2074-2083.
15. Turelli P, Liagre-Quazzola A, Mangeat B, Verp S, Jost S, Trono D. 2008. APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice. J. Virol. 82:6585-6590.
16. Tian Y, Chen WL, Ou JH. 2011. Effects of interferon-α/β on HBV replication determined by viral load. PLoS Pathog. 7:e1002159. doi: 10.1371/journal.ppat.1002159.
17. Boutz DR, Collins PJ, Suresh U, Lu M, Ramírez CM, Fernández- Hernando C, Huang Y, Abreu Rde S, Le SY, Shapiro BA, Liu AM, Luk JM, Aldred SF, Trinklein ND, Marcotte EM, Penalva LO. 2011. Twotiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J. Biol. Chem. 286:18066-18078.
18. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude. 2008. A miR-122, a paradigm for the role of microRNAs in the liver. J. Hepatol. 48:648-656.
19. Yang F, Zhang L, Wang F, Wang Y, Huo XS, Yin YX, Wang YQ, Zhang L, Sun SH. 2011. Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. Neoplasia 13:590-600.
20. Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang SM. 2010. A novel GSK-3 beta-C/EBP alpha-miR-122-insulinlike growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 52:1702-1712.
21. Moore KJ, Rayner KJ, Suárez Y, Fernández-Hernando C. 2011. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu. Rev. Nutr. 31:49-63.
22. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, Qu LH. 2010. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52:1431-1442.
23. Filipowicz W, Grosshans H. 2011. The liver-specific microRNA miR- 122: biology and therapeutic potential. Prog. Drug Res. 67:221-238.
24. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, ørum H. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201.
25. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. 2011. MicroRNA- 122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5= UTR. Proc. Natl. Acad. Sci. U. S. A. 108:4991- 4996.
26. Norman KL, Sarnow P. 2010. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR- 122 involves distinct mechanisms. J. Virol. 84:666-670.
27. Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, Chen L, Chen Y, Duan Z, Meng S. 2010. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem. Biophys. Res. Commun. 398:771-777.
28. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919-922.
29. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. 2009. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15:31-33.
30. Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, Wu E, Ye X, Gao GF, Wang F, Chen Y, Duan Z, Meng S. 2012. Loss of MiR-122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1 modulated P53 activity. Hepatology 55:730-741.
31. Tang H, McLachlan A. 2001. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc. Natl. Acad. Sci. U. S. A. 98:1841-1846.
32. Shlomai A, Paran N, Shaul Y. 2006. PGC-1alpha controls hepatitis B virus through nutritional signals. Proc. Natl. Acad. Sci. U. S. A. 103: 16003-16008.
33. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107:449-455.
34. Vivekanandan P, Thomas D, Torbenson M. 2009. Methylation regulates hepatitis B viral protein expression. J. Infect. Dis. 199:1286-1291.
35. Abe A, Inoue K, Tanaka T, Kato J, Kajiyama N, Kawaguchi R, Tanaka S, Yoshiba M, Kohara M. 1999. Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. J. Clin. Microbiol. 37:2899-2903.
36. Shimizu S, Seki N, Sugimoto T, Horiguchi S, Tanzawa H, Hanazawa T, Okamoto Y. 2007. Identification of molecular targets in head and neck squamous cell carcinomas based on genome-wide gene expression profiling. Oncol. Rep. 18:1489-1497.
37. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. 2007. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 133:1166- 1174.
38. Wang LY, Li YG, Chen K, Li K, Qu JL, Qin DD, Tang H. 2012. Stable expression and integrated hepatitis B virus genome in a human hepatoma cell line. Genet. Mol. Res. 11:1442-1448.
39. He XS, Nanda S, Ji X, Calderon-Rodriguez GM, Greenberg HB, Liang TJ. 2010. Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. J. Interferon Cytokine Res. 30:311-320.
40. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. 2007. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67:6092- 6099.
41. Hsieh JL, Wu CL, Lee CH, Shiau AL. 2003. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1Bdeleted adenovirus through the disruption of p53 function. Clin. Cancer Res. 9:338-345.
42. Ebert MS, Sharp PA. 2010. MicroRNA sponges: progress and possibilities. RNA 16:2043-2050.
43. Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury- Olela F, Ruskeepaa AL, Oresic M, Esau CC, Zdobnov EM, Schibler U. 2009. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 23:1313-1326.
44. Li C, Cao S, Liu Z, Ye X, Chen L, Meng S. 2010. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. Int. J. Cancer 127:1507-1516.
45. Ebert MS, Neilson JR, Sharp PA. 2007. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4:721-726.
46. Kelly EJ, Hadac EM, Cullen BR, Russell SJ. 2010. MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog. 6:e1000820. doi:10.1371/journal.ppat.1000820.
47. Aksoy P, Zhu MJ, Kalari KR, Moon I, Pelleymounter LL, Eckloff BW, Wieben ED, Yee VC, Weinshilboum RM, Wang L. 2009. Cytosolic 5=-nucleotidase III (NT5C3): gene sequence variation and functional genomics. Pharmacogenet. Genomics 19:567-576.
48. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson S, Vartanian JP, Greeve J. 2006. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43:1364-1374.
49. Kim JH, Luo JK, Zhang DE. 2008. The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J. Immunol. 181:6467- 6472.
50. Sarkis PT, Ying S, Xu R, Yu XF. 2006. STAT1-independent cell typespecific regulation of antiviral APOBEC3G by IFN-alpha. J. Immunol. 177:4530-4540.
51. Jost S, Turelli P, Mangeat B, Protzer U, Trono D. 2007. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J. Virol. 81:10588-10596.